Logo image of NTRB

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD

7.46  +0.08 (+1.08%)

After market: 7.49 +0.03 (+0.4%)

Fundamental Rating

3

NTRB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of NTRB is average, but there are quite some concerns on its profitability. NTRB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NTRB had negative earnings in the past year.
NTRB had a negative operating cash flow in the past year.
NTRB had negative earnings in each of the past 5 years.
In the past 5 years NTRB always reported negative operating cash flow.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

NTRB has a worse Return On Assets (-54.59%) than 64.32% of its industry peers.
Looking at the Return On Equity, with a value of -60.96%, NTRB is in line with its industry, outperforming 52.43% of the companies in the same industry.
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROIC N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

NTRB has a Gross Margin (31.59%) which is comparable to the rest of the industry.
NTRB's Gross Margin has improved in the last couple of years.
NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTRB has more shares outstanding
The number of shares outstanding for NTRB has been increased compared to 5 years ago.
NTRB has a worse debt/assets ratio than last year.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 33.29 indicates that NTRB is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 33.29, NTRB belongs to the best of the industry, outperforming 94.05% of the companies in the same industry.
NTRB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
NTRB has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: NTRB outperforms 56.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 33.29
ROIC/WACCN/A
WACC9.76%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

NTRB has a Current Ratio of 4.96. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
NTRB has a better Current ratio (4.96) than 64.86% of its industry peers.
A Quick Ratio of 4.83 indicates that NTRB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.83, NTRB is in the better half of the industry, outperforming 65.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.96
Quick Ratio 4.83
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

6

3. Growth

3.1 Past

NTRB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.01%.
NTRB shows a decrease in Revenue. In the last year, the revenue decreased by -3.18%.
The Revenue has been growing by 53.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.21%
Revenue 1Y (TTM)-3.18%
Revenue growth 3Y30.25%
Revenue growth 5Y53.42%
Sales Q2Q%50.19%

3.2 Future

The Earnings Per Share is expected to grow by 105.73% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 172.96% on average over the next years. This is a very strong growth
EPS Next Y-160.87%
EPS Next 2Y-56.04%
EPS Next 3Y102.51%
EPS Next 5Y105.73%
Revenue Next Year-32.1%
Revenue Next 2Y108.18%
Revenue Next 3Y208.49%
Revenue Next 5Y172.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NTRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

NTRB's earnings are expected to grow with 102.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.04%
EPS Next 3Y102.51%

More info and screens

0

5. Dividend

5.1 Amount

NTRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTRIBAND INC

NASDAQ:NTRB (2/21/2025, 8:00:01 PM)

After market: 7.49 +0.03 (+0.4%)

7.46

+0.08 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-10 2024-12-10
Earnings (Next)04-28 2025-04-28/amc
Inst Owners2.21%
Inst Owner Change-93.67%
Ins Owners54.01%
Ins Owner Change0%
Market Cap82.88M
Analysts82.86
Price Target13.26 (77.75%)
Short Float %7.94%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.78%
PT rev (3m)-27.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.99
P/FCF N/A
P/OCF N/A
P/B 7.38
P/tB 14.73
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.18
BVpS1.01
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.59%
FCFM N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.16%
Cap/Sales 6.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.96
Quick Ratio 4.83
Altman-Z 33.29
F-Score4
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)22.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.21%
EPS Next Y-160.87%
EPS Next 2Y-56.04%
EPS Next 3Y102.51%
EPS Next 5Y105.73%
Revenue 1Y (TTM)-3.18%
Revenue growth 3Y30.25%
Revenue growth 5Y53.42%
Sales Q2Q%50.19%
Revenue Next Year-32.1%
Revenue Next 2Y108.18%
Revenue Next 3Y208.49%
Revenue Next 5Y172.96%
EBIT growth 1Y-22.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.09%
OCF growth 3YN/A
OCF growth 5YN/A